Ocugen stock schedules two November gene therapy appearances

Published on 10/30/2026 at 19:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ocugen stock is set for two November industry appearances focused on its modifier gene therapy platform. The events will feature CEO Shankar Musunuri.

Ocugen sets November investor dates

Ocugen will present its modifier gene therapy platform at the Stifel 2026 Healthcare Conference on November 12.
The company will also join a Cell & Gene Leaders Live panel in London on November 15.

OCGN, US67577C1053, Illustration mit AI erstellt.

Ocugen is preparing two November appearances for investors and industry participants as it advances its modifier gene therapy platform for blindness diseases. The company announced the schedule on October 29 in a release carried by GlobeNewswire.

Ocugen will present at the Stifel 2026 Healthcare Conference in New York on Thursday, November 12, from 10:00 to 10:30 a.m. Eastern time. Chairman, Chief Executive Officer and co-founder Shankar Musunuri is scheduled to lead the presentation.

Pipeline platform remains the focus

The company said the presentation will cover its modifier gene therapy platform. Ocugen is developing programs for inherited retinal diseases and other causes of blindness, including retinitis pigmentosa, Stargardt disease and geographic atrophy, an advanced form of dry age-related macular degeneration.

Ocugen will then participate in Cell & Gene Leaders Live 2026 at The Shard in London on Sunday, November 15. Musunuri is scheduled to join a panel discussion from 3:15 to 4:00 p.m. Greenwich Mean Time. The company said a webcast of the Stifel presentation will be available through its investor website, with a replay available for 30 days.

Upcoming results add a near-term checkpoint

Ocugen has also scheduled its third-quarter 2026 financial results and business update for November 4 at 8:30 a.m. Eastern time. That release will arrive before the two conference appearances and gives investors a nearer-term checkpoint on the development-stage biotechnology company's progress.

Ocugen stock traded at 0.63 euros on Lang & Schwarz at 19:21 Berlin time on Friday, October 30, 2026.